- +62 21 29189160 (ext. 201912)
- manajer.riset.fkui1@gmail.com
- Senin-Jum'at 8.00 s/d 16.00 WIB
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)
Angchaisuksiri, Pantep (6602706106); Amurao-Abiera, Marilou (58972118600); Chou, Sheng-Chien (7401538802); Chewcharat, Pol (57214864605); Chozie, Novie Amelia (57194329830); Gomez, Roy (55211221300); Leng, Tien Sim (58972548700); Lin, Pei-Chin (14008424000); Mai, Nguyen Thi (58972334100); Muda, Zulaiha (26032244800); Seth, Tulika (57203050792); Sosothikul, Darintr (15830686100); Siu-Ming Wong, Raymond (58972548800)
Haemophilia care in Asia: Learning from clinical practice in some Asian countries
2024
Haemophilia
30
3
609
616
7
0
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85189511778&doi=10.1111%2fhae.14998&partnerID=40&md5=db92c75ef8989a532812ecc886fdfde6
Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Philippine Children's Medical Center, Cancer and Hematology Division (Head), Quezon City, Philippines; Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Medical Affairs Manager Pfizer Thailand, Bangkok, Thailand; Division of Hematology Oncology, Department of Child Health Science, Dr. Cipto Mangunkusumo Hospital/Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Emerging Asia Cluster Medical Lead – Rare Disease, Pfizer Singapore, Singapore, Singapore; Director, Haemophilia Centre, Department of Haematology, Singapore General Hospital, Singapore, Singapore; Division of Hematology and Oncology, Department of Pediatrics, Kaohsiung Medical University Hospital; Department of Pediatrics, School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Hemophilia Centre, National Institute of Hematology and Blood Transfusion, Hanoi, Viet Nam; Paediatric Haematology Oncology Unit, Hospital Tunku Azizah Women Children Hospital, Kuala Lumpur, Malaysia; Hematology, AIIMS, New Delhi, India; Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok and Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine, Chulalongkorn, Bangkok, Thailand; Division of Haematology, Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong; Sir YK Pao Centre for Cancer, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong
Background: The healthcare systems in Asia vary greatly due to the socio-economic and cultural diversities which impact haemophilia management. Methods: An advisory board meeting was conducted with experts in haemophilia care from Asia to understand the heterogeneity in clinical practices and care provision in the region. Findings: The overall prevalence of haemophilia in Asia ranges between 3 and 8.58/100,000 patients. Haemophilia A was more prevalent as compared to haemophilia B with a ratio of around 5:1. There is under-diagnosis in the region due to lack of diagnosis, registries and/or lack of appropriate facilities in suburban areas. Most patients are referred to the haematologists by their families or primary care physicians, while some are identified during bleeding episodes. Genetic testing faces obstacles like resource constraints, services available at limited centres and unwillingness of patients to participate. Prophylaxis is offered for people with haemophilia (PWH) with a severe bleeding phenotype. Recombinant factors are approved in most countries across the region and are the preferred therapy. The challenges highlighted for not receiving a high standard of care include patients’ reluctance to use an intravenous treatment, poor patient compliance due to frequency of infusions, budget constraints and lack of funding, insurance, availability and accessibility of factor concentrates. Prevalence of neutralizing antibodies ranged from 5% to 20% in the region. Use of immune tolerance induction and bypassing agents to treat inhibitors depends on their cost and availability. Conclusion: Haemophilia care in Asia has evolved to a great extent. However, some challenges remain for which a strategic approach along with multi-stakeholder involvement are needed. © 2024 The Authors. Haemophilia published by John Wiley & Sons Ltd.
Asia; Delivery of Health Care; Hemophilia A; Hemophilia B; Humans; Prevalence; blood clotting factor 8; blood clotting factor 9; Asia; bleeding prophylaxis; clinical practice; drug cost; gene therapy; genetic counseling; genetic screening; health care access; health insurance; hemophilia; hemophilia A; hemophilia B; human; immunological tolerance; learning; patient care planning; patient compliance; patient identification; prevalence; Review; support group; underdiagnosis; health care delivery; hemophilia A; hemophilia B
Haemophilia Society; Pfizer
Funding text 1: Singapore's healthcare is a co\u2010payment system with government's subsidy depending on patient's family income, with additional funding from the Haemophilia Society. For in\u2010patients co\u2010paying is available through Medishield insurance, patient's Medisave and Government subsidy. While for out\u2010patient treatment, there is support through Government subsidy of about 50
John Wiley and Sons Inc
13518216
38523289
Review
Q1
1145
3338
© 2024 Riset & Pengabdian Masyarakat. All Rights Reserved.